A Randomized Comparison of Nephrectomy Followed by Interferon Alpha 2-b (Intron-A) vs. Interferon Alpha 2-b (Intron-A) Alone in Patients with Advanced Renal Cell Carcinoma
Research committees
Treatment
Publication Information Expand/Collapse
2020
PMid: PMID32352530 | PMC number: PMC7193331
2019
Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research [Review]
PMid: PMID30072304
PMid: PMID31103605 | PMC number: PMC6858992
2017
Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials
PMid: PMID27986655 | PMC number: PMC5370550
PMid: PMID28586789; PMC5710507
2014
Comparison of survival outcomes among cancer patients treated in and out of clinical trials
PMid: PMID24627276 | PMC number: PMC3982777
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
2009
Predictors of survival in advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949 [PMID19100570; PMC3394523]
2008
Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group trial S8949
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Predictors of survival in advanced renal cell carcinoma (RCC): long-term results from Southwest Oncology Group Trial S8949
2004
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis
2002
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy
2001
Nephrectomy followed by interferon alfa 2-b compared with interferon alfa-2b alone for metastatic renal-cell cancer
2000
Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949
Cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group trial 8949